New patent on the prime editing of DNA awarded to Broad Institute's David Liu
The genome editing revolution will be patented. Or at least that’s the case for this latest US patent, awarded Tuesday to the Broad Institute’s David Liu and team for the compositions and methods behind the prime editing of a target DNA molecule (e.g., a genome) that enables a nucleotide change and/or targeted gene mutation, according to the abstract.
Developed in Liu’s lab at the Broad Institute, which famously defeated Jennifer Doudna and UC Berkeley in court over CRISPR-related patents, the idea behind prime editing — dubbed CRISPR 3.0 — was published in Nature in December 2019, and that spawned a startup known as Prime Medicine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,700+ biopharma pros reading Endpoints daily — and it's free.